

Important Contact Information

Name of Doctor

Office Phone

After-hours Phone

My Name

My Phone

Emergency Contact (Name & Phone)

Important Information for Health Care Providers

This patient is being treated with pembrolizumab, which can cause immune-mediated adverse reactions that may appear any time during treatment or even after treatment. Assess patients for signs and symptoms of immune-mediated adverse reactions. Early diagnosis and appropriate management are essential to minimise any consequences of immune-mediated adverse reactions.

For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm aetiology or exclude other causes. Based on the severity of the adverse reaction,

withhold pembrolizumab and administer corticosteroids. Please refer to the SmPC for pembrolizumab, available at www.medicines.ie, for detailed information on monitoring and managing immune-mediated and other adverse reactions with pembrolizumab. Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific immune-mediated adverse reactions.

Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance; Website: www.hpra.ie.

Please consult the Summary of Product Characteristics for KEYTRUDA at medicines.ie or call MSD Medical Information at 01 299 8700 for more information.

Tell your doctor right away if you have any of these symptoms:

Lungs

- Shortness of breath
- Chest pain
- Coughing

Intestines

- Diarrhoea or more bowel movements than usual
- Stools that are black, tarry, sticky, or contain blood or mucus
- Severe stomach pain or tenderness
- Nausea or vomiting

Liver

- Nausea or vomiting
- Feeling less hungry
- Pain on the right side of stomach

- Yellowing of skin or whites of eyes
- Dark urine
- Bleeding or bruising more easily than normal

Kidneys

- Changes in the amount or colour of your urine

Hormone glands

- Rapid heartbeat
- Weight loss or weight gain
- Increased sweating
- Hair loss
- Feeling cold
- Constipation
- Deeper voice
- Muscle aches
- Dizziness or fainting
- Headaches that will not go away or unusual headache

Type 1 diabetes, including diabetic ketoacidosis

- Feeling more hungry or thirsty
- Needing to urinate more often
- Weight loss
- Feeling tired or feeling sick
- Stomach pain
- Fast and deep breathing
- Confusion
- Unusual sleepiness
- A sweet smell to your breath
- A sweet or metallic taste in your mouth
- A different odour to your urine or sweat

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via HPRA Pharmacovigilance; Website: www.hpra.ie. By reporting side effects, you can help provide more information on the safety of this medicine.

Patient Card

For more information, consult the Package Leaflet for KEYTRUDA containing information for the patient at medicines.ie.



MSD

Red Oak North,
South County Business Park,
Leopardstown, Dublin
D18 X5K7, Ireland.
© 2023 Merck & Co., Inc.,
Rahway, NJ, USA and its
affiliates. All rights reserved.

Date of revision:
August 2023

IE-KEY-00783

IMPORTANT

- Do not attempt to treat side effects yourself.
- Do not stop your treatment with pembrolizumab unless you have discussed this with your doctor.
- **Take this card with you at all times**, especially when you travel, whenever you go to the emergency room, or when you must see another doctor.
- Be sure to notify any health care professional you see that you are being treated with pembrolizumab and show them this card.

KEYTRUDA[®]
(pembrolizumab)

May cause some serious side effects which can sometimes become life-threatening and lead to death. These may happen any time during treatment or even after your treatment has ended. You may experience more than one side effect at the same time.

Contact your doctor right away if you develop any signs or symptoms including those not listed on this card. Your doctor may give you other medicines in order to prevent more severe complications and reduce your symptoms. Your doctor may withhold the next dose of pembrolizumab or stop treatment with pembrolizumab.